Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Goldman picks China healthcare stocks for a post-AI trade
Chinese corporate earnings are on a tear, giving investors clues on which stock sectors offer untapped returns, according to Goldman Sachs. Nearly half of MSCI China index constituents beat estimates in the second quarter, with IT and heal…
Notable healthcare headlines for the week: UnitedHealth, Moderna, and Medtronic in focus
Wall Street's major market averages finished lower on Friday after traders and investors digested the latest jobs data, which came in stronger than forecasted. The blue-chip Dow ended 0.5% lower, the benchmark S&P 500 slipped 0.3%, and the…
BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run
BeOne Medicines has delivered an 86.0% gain over the past three years, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. Recent regulatory wins and a higher shar…
The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal
BeOne Medicines recently secured U.S. FDA approvals for TEVIMBRA and ZIIHERA-based regimens in first-line HER2-positive gastroesophageal cancers and entered a voluntary agreement with the U.S. government to expand access to its oncology dr…
BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?
BeOne Medicines AG (NASDAQ:ONC) entered a voluntary agreement with the U.S. government that combines pharmaceutical-tariff protection with commitments on manufacturing, Medicaid participation, and the pricing of future medicines. The agree…
FDA Approval Marks A Turning Point For BeOne Medicines (ONC)
On August 25, BeOne Medicines (NASDAQ:ONC) said the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, a hard-to-treat cancer that strikes more th…
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
On Monday, President Trump announced that his administration has signed separate drug-pricing agreements with nine mid-sized pharmaceutical companies to lower drug prices in the country. These companies include Alcon, Astellas Pharma ALPMY…
AM Markets Need to Know: Nasdaq rebounds in August, Anthropic expands AI capacity, and more
[New York City and London multiple exposure image] Stock index futures pointed to a weaker open on Tuesday, setting Wall Street up for a lower start to September as investors monitored renewed tensions in the Middle East. Here are the five…
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
SAN CARLOS, Calif., September 01, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference…
Trump unveils new drug-pricing accords with CSL, Astellas, and other biotech drugmakers
[Inspecting capsules before production] Dejan Sarec/iStock via Getty Images U.S. President Donald Trump introduced a new set of drug-pricing deals with global pharmaceutical companies and smaller biotechs on Monday, advancing efforts to cu…
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing SAN CARLOS, Calif., August 31, 2026--(BUSINESS WIRE)--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a glob…
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEA ZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analys…
Generative "AI" Macro Data Shows U.S. Impacts
Time now for some fresh generative "AI" data and insight from FRED. Here to help us interpret it is our Chief Equity Strategist and Economist, John Blank. 1. For those who don't know, what is FRED? 2. What is the new data? 3. What does it…
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following…
White House is said to announce drug pricing deals with biotechs
The Trump administration is expected to announce a series of drug pricing deals with several mid-size biotech companies as early as Monday, adding to similar agreements reached with Big Pharma since late last year, Bloomberg News reported…
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ GEA, regardless of PD-L1 status Regimen poised to become standard of care in this diff…
BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?
BeOne Medicines Ltd. - Sponsored ADR (ONC) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ONC's 50-day simple moving average broke out above its 200-day moving average; t…
XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?
The State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides broad exposure to the biotech industry, while the First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) offers a much more concentrated, equal-weighted alternative. Biotec…
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028 SAN CARLOS, Calif. & SEATTLE, August 18, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd.…
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the August 10 agreement, the companies will comb…
BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...
This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% y…
Summit higher as partner Akeso wins China label expansion for lead drug
[Approved red stamp sign.] * Shares of Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) traded higher on Wednesday after the Chinese drug regulator, the National Medical Products Administration, approved a label expansion…
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers Regional rights agreement provides BeOne with exclusive development…
Is BeOne Medicines (ONC) Undervalued Following Its Earnings Beat And Raised Outlook?
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BeOne Medicines (ONC) is back in focus after reporting second quarter 2026 results on 5 August, with revenue and earnings su…
BeOne Medicines Q2 Earnings Call Highlights
Key Points Interested in BeOne Medicines Ltd. - Sponsored ADR? Here are five stocks we like better. Strong second-quarter performance: BeOne Medicines reported revenue of $1.7 billion, up 30% year over year, while GAAP earnings per ADS ros…
BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
BeOne Medicines Ltd. - Sponsored ADR (ONC) reported $1.71 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 29.6%. EPS of $2.05 for the same period compares to $0.84 a year ago. The reported reve…
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year Diluted GAAP Earnin…
Here are the major earnings before the open Wednesday
Major earnings expected before the bell on Wednesday include: * The Walt Disney Company (DIS [https://seekingalpha.com/symbol/DIS]) * Eli Lilly and Company (LLY [https://seekingalpha.com/symbol/LLY]) * Shopify (SHOP [https://seekingalpha.c…
Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Wall Street analysts expect BeOne Medicines Ltd. - Sponsored ADR (ONC) to post quarterly earnings of $1.40 per share in its upcoming report, which indicates a year-over-year increase of 66.7%. Revenues are expected to be $1.66 billion, up…
Most and least shorted mid- to mega-cap healthcare stocks at the end of July
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Short interest data from late July 2026 highlights deeply divided investor sentiment across the healthcare sector. St…
State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio?
Determining whether State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) or First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) fits a portfolio depends on an investor's preference for broad-sector stability or concentrat…
State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio?
Key Points State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to the 0.55% charged by First Trust NYSE Arca Biotechnology Index Fund. First Trust's fund focuses exclusively on 30 bi…
Dell Upgraded, Tesla Downgraded: Updated Rankings on Top Blue-Chip Stocks
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
BeOne Medicines Expands U.S. Manufacturing With $1 Billion Investment
(RTTNews) - BeOne Medicines Ltd. (ONC) announced a $300 million expansion of its flagship manufacturing and R&D center at the Princeton West Innovation Campus in Hopewell, New Jersey, bringing its total U.S. manufacturing investment to mor…
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?
The First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) provides concentrated, high-conviction exposure to biotechnology firms, while the Vanguard Health Care ETF (NYSEMKT:VHT) offers a cheaper, diversified basket across the entir…